Current Edition

Adamas

Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff

As Supernus’ top drug inches toward the patent cliff, the central nervous system-focused drugmaker has struck an M&A deal to quickly expand its portfolio of …

Continue Reading →
Acceleron

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Merck’s new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks …

Continue Reading →